Close

Novavax (NVAX) Begins Phase 1/2 Trial of NanoFlu Vaccine in Older Adults

September 19, 2017 9:05 AM EDT Send to a Friend
Novavax, Inc., (Nasdaq: NVAX) today announced the enrollment of the first participant in a Phase 1/2 clinical trial of its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login